Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 2,942 Shares of Stock

Key Points

• KalVista Pharmaceuticals insider Paul Audhya sold 2,942 shares of stock at an average price of $13.22, resulting in a total transaction of approximately $38,893.
• Following the transaction, Audhya's ownership in the company decreased by 2.40%, leaving him with 119,841 shares valued at around $1.58 million.
• KalVista's stock price declined by 3.1% to $12.99, with analysts recently setting new price targets between $19.00 and $27.00, indicating a favorable outlook for the stock.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul Audhya sold 2,942 shares of KalVista Pharmaceuticals stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total transaction of $38,893.24. Following the completion of the transaction, the insider directly owned 119,841 shares in the company, valued at $1,584,298.02. This represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

KalVista Pharmaceuticals Trading Down 3.1%

Shares of NASDAQ:KALV traded down $0.42 on Monday, hitting $12.99. 543,269 shares of the company were exchanged, compared to its average volume of 775,347. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $16.32. The stock's 50 day moving average price is $13.40 and its 200 day moving average price is $12.39. The firm has a market capitalization of $653.92 million, a P/E ratio of -3.52 and a beta of 0.05.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings data on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period last year, the business posted ($1.07) EPS. On average, equities analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KALV. Wells Fargo & Company MN increased its holdings in KalVista Pharmaceuticals by 29.1% in the fourth quarter. Wells Fargo & Company MN now owns 20,165 shares of the specialty pharmaceutical company's stock valued at $171,000 after buying an additional 4,543 shares in the last quarter. Legal & General Group Plc increased its holdings in KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after buying an additional 1,494 shares in the last quarter. Marshall Wace LLP increased its holdings in KalVista Pharmaceuticals by 691.5% in the fourth quarter. Marshall Wace LLP now owns 117,978 shares of the specialty pharmaceutical company's stock valued at $999,000 after buying an additional 103,072 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in KalVista Pharmaceuticals by 14.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 696,037 shares of the specialty pharmaceutical company's stock valued at $5,895,000 after buying an additional 89,001 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after buying an additional 5,502 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently commented on KALV shares. JMP Securities lifted their price objective on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a research note on Tuesday, July 8th. Leerink Partners lifted their price objective on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a research note on Monday, July 7th. Finally, HC Wainwright boosted their target price on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $26.29.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.